Management

Zoltan Kiss, Ph.D. - He founded ZK Muscle Research biotechnological company in 2021 for which now he serves as the President and CEO. This family-owned company is based, for the most part, on his extensive research showing that the human protein, (ZKPr1), used either in highly purified or recombinant form, can significantly reduce loss of skeletal proteins in obese mice along with normalization of excess visceral (abdominal) fat. The company expects that ZKPr1 will be used as an add-on drug in non-obese and obese people for both conditions.

*About the Founder: Zoltan Kiss, Ph.D., had an extensive academic research career before founding and leading several biotechnological companies. Until 2004, he was Professor and Section Leader at the University of Minnesota. Prior to that, he was a Senior Investigator at the National Cancer Institute (4 years) and held several faculty positions in the U.S. and Europe. Dr. Kiss holds a Ph.D. degree, and his research so far has resulted in 114 peer-reviewed articles and 27 issued international patents as well as 5 filed patent applications on the treatments of cancer cachexia, wounds, and various metabolic disorders including specific treatment of excess visceral fat and loss of muscle proteins in obese mice. All his issued patents are now owned by MNPHARM, LLP, a Minnesota biotech company. Most recently, Dr. Kiss has been focusing on (1) finding effective interventions to normalize excess visceral obesity and determining the nature of relationships between visceral fat and various metabolic disorders including muscle loss in obese and aging mice, (2) methods to prevent cancer cachexia, and (3) using organic compounds to stabilize body weight for periods when treatments with weight loss drugs are stopped.